| Current Price | $17.78 | Mkt Cap | $1.7B |
|---|---|---|---|
| Open | $16.95 | P/E Ratio | -5.44 |
| Prev. Close | $17.78 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $16.47 - $17.92 | Volume | 1,447,775 |
| 52-Wk Range | $8.67 - $25.69 | Avg. Daily Vol. | 922,248 |
| Current Price | $17.78 | Mkt Cap | $1.7B |
|---|---|---|---|
| Open | $16.95 | P/E Ratio | -5.44 |
| Prev. Close | $17.78 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $16.47 - $17.92 | Volume | 1,447,775 |
| 52-Wk Range | $8.67 - $25.69 | Avg. Daily Vol. | 922,248 |
The best Bull and Bear pitches based on recency and number of recommendations.
One of the best pipelines I've seen for a $1.2 billion biotech. Very long term though as important catalysts are in 2016.
I think Fibrogen is vulnerable to a decline especially if the biopharma sector starts taking on water again. The company has a lofty 1.8B valuation despite being behind low-valued competitor Akebia in development of their HIF inhibitor. CTGF antibody… More
Read the most recent pitches from players about FGEN.
Recs
stj1xxx
(< 20)
Submitted: 11/12/2019 1:12:37 PM :
Start Price:
$33.68
NASDAQ:FGEN Score:
-85.91
Great technology
Recs
mdriver78
(65.45)
Submitted: 5/15/2019 3:40:06 PM :
Start Price:
$36.85
NASDAQ:FGEN Score:
-102.15
The source of FGEN's recent problem is confusion over the company’s recently released Phase 3 trial results for roxadustat, a drug intended for use in patients with chronic kidney disease who are on dialysis and have anemia.
A goal for the company in this trial was to show that roxadustat wasn’t inferior to an existing drug used to manage anemia in these patients, on a risk measure called MACE (major adverse cardiac events).
But the language used by FibroGen in its press release confused investors as to the drug’s potential.
Investors are often confused by clinical data, and sometimes when they read positive things in a negative way it can create a buying opportunity.
Recs
Bigsef77
(51.25)
Submitted: 9/14/2018 11:08:48 AM :
Start Price:
$43.65
NASDAQ:FGEN Score:
-119.10
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
GlobeNewswire•September 12, 2018
SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This follows review of the Phase 2 clinical data evaluating pamrevlumab in a placebo-controlled trial and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.
“This Fast Track designation reflects recognition of the great need for a new therapeutic to help patients diagnosed with IPF to reduce the burden and progression of this debilitating disease and another positive step in developing pamrevlumab for the treatment of IPF,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety. “We look forward to advancing pamrevlumab into Phase 3 studies early next year.”
Find the members with the highest scoring picks in FGEN.
King2061x (50.84) Score: +137.77
The Score Leader is the player with the highest score across all their picks in FGEN.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| King2061x | 50.84 | 8/8/2017 |
|
5Y | $50.50 | -64.79% | +72.98% | +137.77 | 0 Comment | |
| sikiliza | < 20 | 5/2/2023 |
|
5Y | $16.58 | +7.24% | +3.46% | -3.78 | 0 Comment | |
| TMFkodyk123 | 36.80 | 8/17/2021 |
|
5Y | $12.03 | +47.75% | -3.28% | -51.03 | 0 Comment | |
| stj1xxx | < 20 | 11/12/2019 |
|
5Y | $33.68 | -47.21% | +38.70% | -85.91 | 1 Comment | |
| monkeyboy2006 | < 20 |
|
|
5Y | $15.30 | +16.21% | +105.78% | -89.57 | 0 Comment | |
| stainsolution | < 20 | 11/4/2019 |
|
5Y | $36.13 | -50.79% | +39.61% | -90.40 | 0 Comment | |
|
bodostar | 67.89 | 10/31/2016 |
|
5Y | $16.95 | +4.90% | +101.41% | -96.52 | 0 Comment |
| mdriver78 | 65.45 | 5/17/2019 |
|
5Y | $36.85 | -51.75% | +50.40% | -102.15 | 1 Comment | |
| gunda7907 | < 20 | 5/20/2015 |
|
5Y | $18.53 | -4.05% | +101.03% | -105.07 | 0 Comment | |
| stegomyeggo | 65.67 |
|
|
3Y | $25.80 | -31.09% | +80.60% | -111.68 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
